intravitreal ranibizumab

ApprovedMonoclonal antibody

intravitreal ranibizumab is one of 95 small molecule programs targeting Choroidal Neovascularization. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Choroidal NeovascularizationActive, not recruiting

Epiretinal MembraneActive, not recruiting

Neovascular GlaucomaActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

GrowthActive, not recruiting

Choroidal NeovascularizationPhase 2

Active, not recruiting

Epiretinal MembranePreclinical

Active, not recruiting

Neovascular GlaucomaApproved

Active, not recruiting

Diabetic Macular EdemaPhase 3

Active, not recruiting

Age-Related Macular DegenerationPhase 2

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

intravitreal ranibizumab

Roche

Approved

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Herceptin

OOrganon and Co

Preclinical

4 6

Glucophage

EMD Serono

Preclinical

2 7

EGRIFTA WR

TTheratechnologies

Preclinical

2 8

Neupogen

EEastern Cooperative Oncology Group

Preclinical

1 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

1 10

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Diabetic Macular Edema

NCT04108156

Clinical

Trials by Indication[1]

Diabetic Macular Edema4 trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04503551·174 enrolled

Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection

Completed·FFundació Institut Germans Trias i Pujol··NCT02933905·38 enrolled

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Terminated·—·Phase 4·NCT04991350·5 enrolled

Show 1 more trial

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04108156·672 enrolled

Treatment3 trials

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

Completed·—·Phase 4·NCT03690947·72 enrolled

Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab

Completed·CCalifornia Retina Consultants·Phase 4·NCT02107131·40 enrolled

Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy

Completed·SSultan Qaboos University·Phase 2·NCT03763227·13 enrolled

Neovascular Glaucoma2 trials

Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Completed·SSiriraj Hospital·Phase 4·NCT01922154·15 enrolled

Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

Unknown status·LLEANDRO CABRAL ZACHARIAS·Phase 3·NCT02914626·28 enrolled

Epiretinal membrane1 trial

Treatment of Epiretinal Membranes With Ranibizumab

Completed·QQueen's University·N/A·NCT01238393·11 enrolled

Monotherapy1 trial

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Completed·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT00429962·40 enrolled

8 more indications

Choroidal Neovascularization1 trial

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Completed·UUniversity Hospital, Bonn·Phase 2·NCT00510965·10 enrolled

ESS1 trial

Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Unknown status·UUniversity of Malaya·N/A·NCT01626339·30 enrolled

Growth1 trial

Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Completed·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT03115255·17 enrolled

Anti-inflammatory Therapy1 trial

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

Completed·JJHSPH Center for Clinical Trials·Phase 3·NCT02623426·194 enrolled

Trial1 trial

Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

Completed·UUniversity Hospital, Bonn·Phase 2·NCT00504400·10 enrolled

Phase II1 trial

Phase II Combination Steroid and Anti-VEGF for Persistent DME

Completed·JJaeb Center for Health Research·Phase 2·NCT01945866·129 enrolled

Age-Related Macular Degeneration1 trial

Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Completed·MMedical University of Vienna·Phase 2·NCT01162746·40 enrolled

Outcome1 trial

Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab

Unknown status·UUnity Health Toronto·Phase 4·NCT03056092·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for intravitreal ranibizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravitreal ranibizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravitreal ranibizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: Roche

intravitreal ranibizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Diabetic Macular Edema4 trials

Treatment3 trials

Neovascular Glaucoma2 trials

Epiretinal membrane1 trial

Monotherapy1 trial

Choroidal Neovascularization1 trial

ESS1 trial

Growth1 trial

Anti-inflammatory Therapy1 trial

Trial1 trial

Phase II1 trial

Age-Related Macular Degeneration1 trial

Outcome1 trial

References

Drug Info

Quick Facts

Related News